TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 0.800nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 0.900nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 0.900nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 1.10nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 1.10nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 2.60nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 2.60nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 3nMAssay Description:A radiotracer flux assay used to determine ion flux activity of voltage-gated sodium channels in a high-throughput microplate-based format. The assay...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 3nMAssay Description:The assay is based on the guanidine influx assay described by Reddy, N.
L., et al., J. Med. Chem. (1998), 41(17):3298-302. The guanidine influx
ass...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 3nMAssay Description:Inhibition of human NaV1.7 expressed in HEK293 cells by [14C]guanidinium influx assayMore data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 3.30nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 3.30nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 3.30nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 4nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 4.80nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 5nMAssay Description:The assay is based on the guanidine influx assay described by Reddy, N.
L., et al., J. Med. Chem. (1998), 41(17):3298-302. The guanidine influx
ass...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 5nMAssay Description:A radiotracer flux assay used to determine ion flux activity of voltage-gated sodium channels in a high-throughput microplate-based format. The assay...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 6nMAssay Description:Inhibition of human NaV1.7 expressed in HEK293 cells by [14C]guanidinium influx assayMore data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 6.80nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 6.80nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 7nMAssay Description:A radiotracer flux assay used to determine ion flux activity of voltage-gated sodium channels in a high-throughput microplate-based format. The assay...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 7nMAssay Description:The assay is based on the guanidine influx assay described by Reddy, N.
L., et al., J. Med. Chem. (1998), 41(17):3298-302. The guanidine influx
ass...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 7nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 7.90nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 8.60nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 11nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 11nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 12nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 13nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 15nMAssay Description:The assay is based on the guanidine influx assay described by Reddy, N.
L., et al., J. Med. Chem. (1998), 41(17):3298-302. The guanidine influx
ass...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 15nMAssay Description:A radiotracer flux assay used to determine ion flux activity of voltage-gated sodium channels in a high-throughput microplate-based format. The assay...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 20nMAssay Description:Inhibition of human NaV1.7 expressed in HEK293 cells by [14C]guanidinium influx assayMore data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 21.6nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 23nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 23nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 28nMAssay Description:Inhibition of human Nav1.7More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 30nMAssay Description:Inhibition of human NaV1.7 expressed in HEK293 cells by [14C]guanidinium influx assayMore data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 30nMAssay Description:Inhibition of human NaV1.7 expressed in HEK293 cells by [14C]guanidinium influx assayMore data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 31.7nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 32nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 33nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 33nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 38nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 38nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 38.1nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 40nMAssay Description:Inhibition of human NaV1.7 expressed in HEK293 cells by [14C]guanidinium influx assayMore data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 40nMAssay Description:Inhibition of human NaV1.7 expressed in HEK293 cells by [14C]guanidinium influx assayMore data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 49.9nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 50nMAssay Description:Inhibition of human Nav1.7 expressed in HEK cells assessed as reduction in sodium current at -60 mV holding potential by PatchXpress platform based w...More data for this Ligand-Target Pair
TargetSodium channel protein type 9 subunit alpha(Homo sapiens (Human))
Xenon Pharmaceuticals
US Patent
Xenon Pharmaceuticals
US Patent
Affinity DataIC50: 50.7nMAssay Description:The following patch voltage clamp electrophysiology studies were performed on representative compounds of the invention using human embryonic kidney ...More data for this Ligand-Target Pair